Indaptus Therapeutics Inc
indaptusrx.comWhat Do They Do?
Develops an experimental, bacteria-based immunotherapy platform for cancer and viral diseases.
10-K for FY2025, filed Mar 17, 2026We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 17, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$1.8MView ↗
- ▼ −66% (Loss)
- vs −$5.2M in Q2 FY2025
-
Apr 3, 2026
CFO resigned and a new CFO was appointed
Nir Sassi left the CFO role, and Yu Ding was appointed CFO.
Sources
8-K, filed Apr 3, 2026
Nir Sassi resigned as Chief Financial Officer on April 1, 2026. Mr. Sassi’s resignation is not based on any disagreement with the Company…View ↗
-
Mar 24, 2026
Preferred-stock interests changed hands; both co-CEOs resigned
Lazar sold preferred-stock interests to purchasers, while he and Meckler resigned as co-CEOs.
Sources
8-K, filed Mar 24, 2026
The Company has been advised that, pursuant to a share sale agreement (the “March 2026 SPA”), on March 23, 2026, David Lazar sold, in…View ↗
From clinical development to strategic options
The older report described plans to advance the lead candidate's clinical trial; the latest report says enrollment has ended, no new trial is planned, and the company is evaluating an investment in or acquisition of another company.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026
Loading...
